Chonluten vs Follistatin 344
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
ChonlutenAnabolic & IGF
Follistatin 344- Summary
- Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
- Follistatin 344 is a recombinant form of the endogenous follistatin protein. It inhibits myostatin and activin — the primary negative regulators of muscle growth — potentially removing the genetic ceiling on muscle development. It is one of the most theoretically powerful anabolic compounds but is experimental with limited human data.
- Half-Life
- Short (minutes for the peptide); sustained gene-regulatory effects
- ~24–36 hours
- Admin Route
- SubQ, Oral
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 100 mcg
- Frequency
- Daily for 10–30 days
- Once daily
- Key Benefits
- Supports bronchial mucosal regeneration and repair
- May improve mucociliary clearance in chronic respiratory conditions
- Anti-inflammatory effects on bronchial epithelium
- Pulmonary anti-aging and tissue preservation
- Supports lung function in COPD and chronic bronchitis
- Well tolerated in combination with other Khavinson bioregulators
- Short tripeptide with efficient cellular penetration
- Inhibits myostatin — removes muscle growth ceiling
- Significant increases in muscle mass and strength
- Reduces fat mass
- Promotes bone density
- May stimulate hair follicle cycling
- Anti-fibrotic effects in muscle tissue
- Synergistic with IGF-1 and other anabolic peptides
- Side Effects
- Generally well tolerated
- Mild injection site reactions possible
- No significant adverse pulmonary events reported
- Muscle soreness (from rapid hypertrophy)
- Potential reproductive effects (activin inhibition)
- Unknown long-term safety profile
- Possible esophageal effects at high doses (animal data)
- Stacks With
- —
- —